The CD19 CAR is identical to JK11, except for the scFv, and resembles the construct used in tisagenlecleucel (fmc63scFv_CD8aTM/spacer_41BB-z), which is approved for use against leukemia [1]. This evidence concerns the gene CD19 and leukemia.